HOPE Therapeutics, Inc., (“HOPE,” the “Company”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. (“NRx”) (Nasdaq:NRXP), announces the signing of a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, LLC, LLC (Neurospa). Neurospa operates six interventional psychiatry clinics on Florida’s Gulf Coast and will constitute a key element of HOPE’s Florida network going forward. Neurospa is revenue generating and EBITDA positive. Neurospa leverages state-of-the-art interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato®, augmented by traditional psychiatry and talk therapy.
Read the full article: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC //
Source: https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-binding-letter-of-intent-with-neurospa-tms-holdings-llc-for-expansion-of-its-planned-international-network-of-interventional-psychiatry-clini-302408763.html